PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy

NCT07463248 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Tislelizumab Combined With TKI
DRUG: Fecal Microbiota Transplantation
RADIATION: PULSAR

Sponsor

Wang Xin